⇨ Novartis has joined the syndicate backing a $13.1 million round for Tokyo-based Anaeropharma, which is targeting hypoxic solid tumors. Novartis, Shinsei Corporate Investment Limited and Seventure Partners led joined as new investors alongside Innovation Network Corporation of Japan and Mitsubishi UFJ Capital’s managed fund.
⇨ Eli Lilly is investing $52 million into a new research program with Purdue University focused on new and better injectable tech and predictive models for clinical success to help improve the odds of winning in the clinic.
⇨ Silence Therapeutics is dragging Alnylam and The Medicines Company into a UK court, contesting the IP on four key programs: patisiran, fitusiran, givosiran and inclisiran. Alnylam and The Medicines Company are partnered on inclisiran. In its statement, Silence – which is listed on the London exchange – says it is looking for supplementary protection certificates.
⇨ The Alzheimer’s Drug Discovery Foundation is providing a $750,000 grant to AgeneBio for their work on a GABAA discovery program.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription